Financial

News
Shingrix helps GSK make a solid start in 2023

Shingrix helps GSK make a solid start in 2023

GSK managed to beat analysts’ revenue predictions for the first quarter of the year, despite an 8% decline in turnover pegged back by declines in COVID-19-related products

News
Roche's Thomas Schinecker

Vabysmo vaults into Roche’s top growth spot

The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo, heading for blockbuster territory after posting sales of